IRX-2 Regimen

IRX-2 Regimen is a combination immunotherapeutic protocol designed to stimulate the immune system in patients with cancer, particularly head and neck squamous cell carcinoma (HNSCC). The regimen centers on IRX-2, a biologic product containing a mixture of cytokines (including IL-2, IL-1β, IL-6, IL-8, TNFα, GM-CSF, and IFNγ) derived from human peripheral blood mononuclear cells stimulated with phytohemagglutinin. The full regimen typically includes an initial dose of cyclophosphamide followed by 10 days of regional perilymphatic or subcutaneous injections of IRX-2 and daily oral indomethacin, zinc-containing multivitamins, and omeprazole. Mechanistically, the regimen aims to enhance dendritic cell maturation and T-cell/NK-cell activation while increasing tumor-infiltrating lymphocytes (TILs), thereby overcoming tumor-mediated immunosuppression. Clinical trials have shown that the regimen is generally well tolerated but has not demonstrated statistically significant improvements in event-free survival as neoadjuvant therapy compared to standard care; however, trends suggest possible benefit in higher-stage disease or certain subgroups[1][5][7][8].

Brand names

IRX-2 RegimenIRX2 RegimenIRX 2 Regimen

Other names

Citoplurikin